Education
Osgoode Hall Law School (2016) JD
University of Toronto (2013) PhD (Chemistry)
Memorial University of Newfoundland (2008) BSc (Chemistry)

Bar Admissions
Ontario (2017)

Practice Areas
Intellectual Property

Contact
T 416-849-4564
cmcclary@litigate.com

Corey McClary

COREY MCCLARY
is an associate at Lenczner Slaght.

Corey's practice is primarily focused on intellectual property law, with an emphasis on pharmaceutical patent litigation. Corey has experience advising clients on complex disputes, including actions under the *Patented Medicines (Notice of Compliance) Regulations*, patent infringement and impeachment actions, and judicial review proceedings. Corey also regularly provides strategic patent and regulatory advice.

Prior to joining Lenczner Slaght, Corey summered, articled and practiced in the intellectual property litigation group at a leading international law firm in Toronto.

Before attending law school, Corey obtained a Ph.D. in organic chemistry. His graduate research focused on developing methods for the regioselective functionalization of carbohydrates and measuring the strength of non-covalent interactions. His research has been published in peer-reviewed scientific journals.

RECOGNITION

- Best Lawyers in Canada (2025)
  Ones to Watch – Intellectual Property

SELECT CASES

- **The NOCO Company, Inc. v Canadian Tire Corporation, Limited –** Counsel to Canadian Tire Corporation, Limited in an action for patent infringement in the Federal Court in respect of Canadian Patent No. 2,916,782.
- **Merck Canada Inc v The Minister of Health –** Counsel to Merck Canada Inc. in a judicial review proceeding in the Federal Court regarding an application for a certificate of supplementary protection for Canadian Patent No. 2,670,892 and BELSOMRA.
- **Gilead Sciences, Inc et al v Pharmascience Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
- **Bernard Charles Sherman v Pfizer Canada Inc –** Counsel to Pfizer Canada Inc. and Pfizer Inc. in an action for patent infringement in the Federal Court in respect of Canadian Patent No. 2,355,347.

- **Akebia Therapeutics Inc v Fibrogen Inc –** Counsel to FibroGen Inc. and AstraZeneca AB in an impeachment action in the Federal Court in respect of Canadian Patent Nos. 2,468,083, 2,467,689, and 2,526,496.
- **Gilead Sciences, Inc et al v JAMP Pharma Corporation –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,990,210.
- **Gilead Sciences, Inc et al v Natco Pharma (Canada) Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
- **Merck Canada Inc v The Minister of Health –** Counsel to Merck Canada Inc. in a judicial review proceeding in the Federal Court in regards to a patent listing for KEYTRUDA.
- **Gilead Sciences Inc, et al v JAMP Pharma Corporation –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
- **Genentech Inc. et al v Amgen Canada Inc. –** Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court actions under the *PMNOC Regulations* in respect of trastuzumab (HERCEPTIN), which were the first actions under the new regime.
- **Novo Nordisk A/S et al v Teva Canada Limited –** Counsel to Novo Nordisk A/S and Novo Nordisk Canada Inc. in Federal Court actions under the *PMNOC Regulations* in respect of liraglutide (VICTOZA).
- **Gilead Sciences, Inc et al v Apotex Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
- **Gilead Sciences, Inc et al v Natco Pharma (Canada) Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
- **Gilead Sciences, Inc et al v Apotex Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
- **Genentech Inc v Celltrion Healthcare Co –** Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court actions under the new *PMNOC Regulations* in respect of trastuzumab (HERCEPTIN), which were the first actions under the new regime.

SELECT PUBLICATIONS AND PRESENTATIONS

- **Organoboron-Promoted Regioselective Glycosylations in the Synthesis of a Saponin-Derived Pentasaccharide from Spergularia ramosa –** Corey McClary co-authored the article *Organoboron-Promoted Regioselective Glycosylations in the Synthesis of a Saponin-Derived Pentasaccharide from Spergularia ramosa,* published in The Journal of Organic Chemistry.
- **Applications of Organoboron Compounds in Carbohydrate Chemistry and Glycobiology: Analysis, Separation, Protection and Activation –** Corey McClary co-authored the article *Applications of Organoboron Compounds in Carbohydrate Chemistry and Glycobiology: Analysis, Separation, Protection and Activation,* published in Carbohydrate Research.
- **Anion Receptors Composed of Hydrogen- and Halogen-Bond Donor Groups: Modulating Selectivity With Combinations of Distinct Noncovalent Interactions –** Corey McClary co-authored the article *Anion Receptors Composed of Hydrogen- and Halogen-Bond Donor Groups: Modulating Selectivity With Combinations of Distinct Noncovalent Interactions*

, published in the Journal of the American Chemical Society.

- **Ligand Directed Self-Assembly vs. Metal Ion Coordination Algorithm - When Does the Ligand or the Metal Take Control? –** Corey McClary co-authored the article *Ligand Directed Self-Assembly vs. Metal Ion Coordination Algorithm - When Does the Ligand or the Metal Take Control?*, published in Dalton Transactions.

BLOG POSTS

- **Fall Regulatory Round Up – The Shifting Shape of the Canadian Landscape – Fall Regulatory Round Up**

  Activity abounds on the regulatory landscape from modernization and transparency initiatives to consultations, collaborations, and even potential implementations. Our Fall Regulatory Round Up highlights significant developments for drug products and patents that are of interest to those in the life sciences and biotech spaces. We will be following these important regulatory initiatives as they continue to unfold and will provide updates of interest.

SELECT NEWS ARTICLES

- **Lenczner Slaght Litigators Recognized as the Best Lawyers in Canada –** In the 2025 edition of *Best Lawyers in Canada*, Lenczner Slaght is proud to receive 168 total rankings, with 45 of our expert litigators recognized for their expertise across 25 practice areas.
- **Corey McClary Joins Lenczner Slaght's IP Team –** Canada's leading litigation firm continues to grow its expert Intellectual Property Group with the addition of another exceptional lawyer, Corey McClary.

PROFESSIONAL ACTIVITIES

- Toronto Intellectual Property Group
- Ontario Bar Association